MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Tuesday, September 15, 2009

Investigators Recruiting for Study of Duloxetine Hydrochloride to Treat Neuropathic Pain in MS

Summary: Investigators in the United States (US) are currently recruiting approximately 200 people with all types of MS who are experiencing central neuropathic pain for a clinical research study to determine if the investigational use of the oral study drug, duloxetine hydrochloride, versus placebo, is safe and effective at reducing neuropathic pain associated with MS. The study is sponsored by Eli Lilly and Company.

Rationale: Approximately 55% of people with MS experience pain. There are two types of chronic pain caused by MS – neuropathic pain (caused by nerve damage) and non-neuropathic pain (caused by muscle spasms or contractions). Neuropathic pain is often described as burning, stabbing, and shooting pain in the legs and arms; and numbness, tingling, prickly, or “pins and needles” sensations. The purpose of this study is to evaluate the investigational use of duloxetine hydrochloride to determine if it reduces neuropathic pain experienced by those with MS. The drug being studied belongs to the group of medications known as selective serotonin and norepinephrine reuptake inhibitors (SSNRIs). The study drug has not been approved for the treatment of MS or MS pain.

Click here to continue reading from the MS Society website and to learn where you can apply for this research study


No comments: